Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

No OS Data Available , No Buyout

|About: AVEO Pharmaceuticals, Inc. (AVEO)
Summary

Tivozanib is only viable asset of AVEO. if its OS data finally cannot allay FDA concern. AVEO dooms.

No OS data available, not any companies would be interested to buy AVEO.  Said 800M to 1 Billion buyout ( almost 8times current value ) is simple pump scheme.

Ficlatuzumab plus cytarabine IS only in phase Ib, result not impressive compare to cytarabine alone at most.

compare to AVEO cash value , unpredictable OS data ( expected available at Q4 ) at that time, it is really alive or die moment ! Although Tivozanib was approved by EU and two other countries , but it seems non profitable up to now. while the first line treatment for mRCC will soon be fundmentally changed to IO comblined with TKI...  

Disclosure: I/we have no positions in any stocks mentioned, but may initiate a short position in AVEO over the next 72 hours.